Rhelion unit Filament Health ships PEX010 for Phase 3 psilocybin trial

Rhelion Life Sciences' Filament Health has shipped PEX010 botanical psilocybin to Bruyère Health Research Institute for a Phase 3 trial targeting 120 participants in palliative care across seven Canadian sites.